Detalhe da pesquisa
1.
Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.
Am J Kidney Dis
; 77(2): 255-263, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32771648
2.
Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD.
Kidney Int Rep
; 6(4): 1032-1040, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33912753
3.
Developing a patient-centred tool for pain measurement and evaluation in autosomal dominant polycystic kidney disease.
Clin Kidney J
; 14(11): 2338-2348, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34754429
4.
Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.
BMJ Open
; 8(5): e022859, 2018 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29743334
5.
Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey.
Clin Kidney J
; 10(3): 305-309, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28616208
6.
Successful restoration of arteriovenous dialysis access patency after late intervention.
Clin Kidney J
; 8(1): 82-6, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25713715
7.
Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease.
Nephron
; 129(3): 197-201, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25720849